Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Clinical Response to Methylphenidate in Pediatric ADHD Using ERPs
NCT02695355Phase 2Completed
- Sponsor
- Ostfold Hospital Trust
- Start
- Oct 2006
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Ostfold Hospital Trust. Primary endpoint: Classification as responders (REs) or non-responders (non-REs) at 4 weeks. Started Oct 2006; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02695355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695355.